Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

Journal of Infectious Diseases

Volumn 213, Issue 6, 2016, Pages 922-929

  Sobhanie, Mahdee ^a   Matsuoka, Yumiko ^b   Jegaskanda, Sinthujan ^b,d   Fitzgerald, Theresa ^a   Mallory, Raburn ^c   Chen, Zhongying ^c   Luke, Catherine ^b   Treanor, John ^a   Subbarao, Kanta ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MEDIMMUNE   (United States)

^d PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

Author keywords

immune memory; live vaccine; pandemic influenza

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BODY ACHE; CHILL; CONTROLLED STUDY; COUGHING; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; EYE IRRITATION; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA A VIRUS (H7N9); INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; NOSE OBSTRUCTION; OTALGIA; PAIN; PRIORITY JOURNAL; RHINORRHEA; SINGLE DRUG DOSE; SORE THROAT; TREATMENT RESPONSE; ADOLESCENT; AGING; BLOOD; DRUG ADMINISTRATION; FEMALE; IMMUNOLOGY; INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PANDEMICS; PHYSIOLOGY; TIME FACTOR; VIRUS REPLICATION; VIRUS SHEDDING; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; AGING; ANTIBODIES, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; TIME FACTORS; VIRUS REPLICATION; VIRUS SHEDDING; YOUNG ADULT;

EID: 84964866294     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv526     Document Type: Article

References (26)

1. Gao H-N, Lu H-Z, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85.
2. Ai J, Huang Y, Xu K, et al. Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu province, China, 2013. Euro Surveillance 2013; 18:20510.
3. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis 2014; 58:1095-103.
4. Mulligan MJ, Bernstein DI, Winokur PL, et al. Serological responses for an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1409-19.
5. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesathasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014; 6:234ra55.
6. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356: 685-96.
7. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9.
8. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9.
9. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953-60.
10. Talaat KR, Karron RA, Luke CJ, et al. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011; 29:3144-8.
11. Talaat KR, Karron RA, Liang PH, et al. An open-label, phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses 2013; 7:66-73.
12. Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009; 27:3744-53.
13. Talaat KR, Luke CJ, Khurana S, et al. A live attenuated influenza A (H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014; 209:1860-9.
14. Babu T, Levine M, Fitzgerald T, et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibdy response to inactivated H7N7 influenza vaccine. Vaccine 2014; 32:6798-804.
15. Chen Z, Baz M, Lu J, et al. Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol 2014; 88:7016-23.
16. Lorbetskie B, Wang J, Gravel C, et al. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011; 29:3377-89.
17. Karron Ruth A, Callahan K, Luke C, et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009; 199:711-6.
18. Shu B, Wu KH, Emery S, et al. Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol 2011; 49:2614-9.
19. Jin H, Lu B, Zhou H, et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (Flu Mist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003; 306:18-24.
20. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
21. Jegaskanda S, Job ER, Kramski M, et al. Cross-reactive influenzaq-specific antibody-dependent cellular cytotoxicity antibodies I the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48.
22. Jegaskanda S, Vandenberg K, Laurie K, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J Infect Dis 2014; 201:1811-22.
23. Ledgerwood JE, Wei C-J, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase I open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24.
24. Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: A randomized phase I study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 354:418-22.
25. Di Lillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc[gamma]R interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-51.
26. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6.